Hossein-Ardeschir Ghofrani
Overview
Explore the profile of Hossein-Ardeschir Ghofrani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
5546
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Preston I, Badesch D, Ghofrani H, Gibbs J, Gomberg-Maitland M, Hoeper M, et al.
Eur Respir J
. 2025 Feb;
PMID: 39978862
Background: SOTERIA (NCT04796337) is an ongoing open-label study evaluating long-term safety, tolerability, and efficacy of sotatercept in participants with pulmonary arterial hypertension (PAH). Methods: Eligible adults with PAH on stable...
2.
Hoeper M, Rosenkranz S, Badesch D, Humbert M, Langleben D, McConnell J, et al.
Respir Med
. 2024 Dec;
236:107910.
PMID: 39667586
Background: Risk stratification is an essential part of evaluating disease severity in patients with pulmonary arterial hypertension (PAH). This study applied the 4-strata COMPERA 2.0 risk model to the Phase...
3.
Kim N, DArmini A, Howard L, Jenkins D, Jing Z, Mayer E, et al.
Pulm Ther
. 2024 Nov;
11(1):101-116.
PMID: 39520648
Introduction: Evidence for use of pulmonary arterial hypertension targeted-therapies in patients with chronic thromboembolic pulmonary hypertension (CTEPH) is limited. In MERIT-1, the endothelin receptor antagonist macitentan improved hemodynamic and functional...
4.
Kremer N, Schaefer S, Yogeswaran A, Rako Z, Ghofrani H, Seeger W, et al.
Am J Respir Crit Care Med
. 2024 Oct;
210(12):1486-1490.
PMID: 39404674
No abstract available.
5.
Kim N, Channick R, Delcroix M, Madani M, Pepke-Zaba J, Borissoff J, et al.
Eur Respir J
. 2024 Sep;
64(4).
PMID: 39326918
Background: SELECT was the first global randomised controlled trial of selexipag with standard of care in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension. Methods: SELECT was a multicentre,...
6.
Sitbon O, Skride A, Feldman J, Sahay S, Shlobin O, McLaughlin V, et al.
Lancet Respir Med
. 2024 Sep;
12(11):865-876.
PMID: 39307144
Background: The role of serotonin in pulmonary arterial hypertension has been extensively studied in recent decades, with preclinical data strongly indicating involvement in disease pathogenesis; however, clinical studies have yielded...
7.
Rosenkranz S, Ghofrani H, Hoeper M, Langleben D, Hegab S, Rahner C, et al.
J Heart Lung Transplant
. 2024 Sep;
44(2):135-146.
PMID: 39236972
Background: There is limited evidence to support treatment recommendations in patients with pulmonary arterial hypertension (PAH) and comorbidities. To investigate the impact of riociguat treatment in this patient population, we...
8.
Shlobin O, Adir Y, Barbera J, Cottin V, Harari S, Jutant E, et al.
Eur Respir J
. 2024 Aug;
64(4).
PMID: 39209469
Pulmonary hypertension (PH) associated with chronic lung disease (CLD) is both common and underrecognised. The presence of PH in the setting of lung disease has been consistently shown to be...
9.
Tello K, Yogeswaran A, Majeed R, Kiely D, Lawrie A, Brittain E, et al.
Chest
. 2024 Aug;
167(1):224-240.
PMID: 39182575
Background: Patients with COPD frequently demonstrate pulmonary hypertension (PH). Severe PH in patients with COPD, identified by pulmonary vascular resistance (PVR) of > 5 Wood units (WU), is closely linked...
10.
Ghofrani H, Gomberg-Maitland M, Zhao L, Grimminger F
Nat Rev Cardiol
. 2024 Aug;
22(2):105-120.
PMID: 39112561
Substantial progress has been made in the management of pulmonary arterial hypertension (PAH) in the past 25 years, but the disease remains life-limiting. Established therapies for PAH are mostly limited...